最新ニュース Nuvation Bio (NYSE:NUVB) 株価情報

NUVATION BIO INC

Nuvation Bio

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

Nuvation Bio Inc

<p>Tidal Financial Group today announced that the Board of Trustees of Tidal Trust II (the "Trust") has authorized a reverse stock split of the Defiance Daily Target 2X Short MSTR ETF (Ticker: SMST), listed on The Nasdaq Stock Market, LLC. The reverse split is scheduled to take effect after the close of trading on May 22, 2025.</p>
<p>Under the terms of the 1-for-20 reverse stock split, every twenty shares of SMST will be consolidated into one share. This adjustment will reduce the number of shares outstanding by approximately 95%. As a result, both the fund's per-share net asset value (NAV) and opening market price on May 23, 2025, will be adjusted proportionally—approximately twenty times their pre-split values. SMST will begin trading on a split-adjusted basis when markets open on May 23, 2025.</p>
<p>This action is designed to optimize the fund's capital structure and enhance its accessibility to a broader base of investors. While the number of shares held will change, the total dollar value of an investor's holdings will remain unaffected. For instance, an investor holding 1,000 shares at a NAV of $10 before the split will own 50 shares at a NAV of $200 after the split—retaining the same $10,000 investment value.</p>


SMST

Tidal Financial Group Announces Board Of Trustees Of Tidal Trust II Authorizes Reverse Stock Split For Defiance Daily Target 2X Short MSTR ETF, Effective May 22

WIIM

Fomento Economico Mexicano S.A.B. De C.V.

Fomento Economico Mexicano shares are trading higher after the company announced a $250 million accelerated share repurchase agreement.

<p>BofA Securities analyst Jessica Reif Ehrlich maintained a Buy rating on <strong>Charter Communications, </strong><span style="box-sizing: border-box; margin: 0px; padding: 0px;"><strong>Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) last Friday, with a <a href="https://www.benzinga.com/quote/CHTR/analyst-ratings" target="_blank" rel="noopener">price target of $450</a></span>.</p>
<p>Ehrlich noted that Charter had announced an agreement to merge with privately held Cox Communications for an equity purchase consideration of $21.9 billion and the assumption of $12.6 billion in Cox debt and lease obligations.</p>
<p>The $21.9 billion equity consideration is comprised of $11.9 billion in common units, $6 billion notional value in preferred units, and $4 billion in cash, the analyst said.</p>
<p><strong><em>Also Read:</em></strong><em> <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/05/45465922/charter-seals-34-5-billion-cox-merger-deal-creating-powerhouse-to-battle-streaming-wireless-rivals" rel="noreferrer noopener">Charter Seals $34.5 Billion Cox Merger Deal, Creating Powerhouse To Battle Streaming, Wireless Rivals</a></em></p>
<p>The combined entity's pro forma economic ownership will be 67% Charter, 23% Cox, and 10% Advance/Newhouse, according to Ehrlich. She views the $33.9 billion transaction as value accretive, noting it implies a ~6.44x EV/2025E EBITDA multiple before synergies. With $500 million in synergies—likely a conservative estimate—the multiple drops below 6x by year three.</p>
<p>Ehrlich said the deal will expand Charter's reach to 69.5 million passings, 37.6 million customers, and 35.9 million broadband subscribers. It also allows Charter to apply its pricing and packaging strategy across an additional 12.3 million passings and pursue mid-sized commercial and enterprise markets more aggressively.</p>
<p>As per Ehrlich, the deal should not present significant regulatory hurdles and should likely close in mid-2026. The companies do not have overlapping footprints, and 69.5 million passings is only ~5 million larger than <strong>Comcast Corp</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) (64 million) and also not significantly larger than <strong>AT&amp;T Inc&#8217;s</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>) (and AT&amp;T also offers nationwide wireless).</p>
<p>Time Warner Cable&nbsp;/Charter deal in 2015/2016 received regulatory approval in less than 12 months, and the environment has become significantly more competitive.</p>
<p>Ehrlich noted that Comcast is unlikely to present a competing bid due to a likely more difficult regulatory path.</p>
<p>The analyst expects the Cox merger to boost revenue growth across broadband, video, and mobile, improve margins, increase free cash flow, and reduce leverage. While integration may pose challenges, Charter's strong execution history and improving broadband and video trends should support EBITDA growth.</p>
<p><strong>CHTR</strong> <strong>Price Action:</strong> At the last check on Monday, Charter Communications stock was down 2.1% to $418.27.</p>
<p><strong>Read Next:</strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/45047933/charters-strong-network-new-bundles-drive-analyst-optimism-for-long-term-growth" target="_blank" rel="noreferrer noopener">Charter&#8217;s Strong Network, New Bundles Drive Analyst Optimism For Long-Term Growth</a></strong></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


News

Price Target

Reiteration

Analyst Ratings

Trading Ideas

CHTR

CMCSA

Charter's Proposed Cox Deal Could Challenge Comcast, Surpass AT&T In Broadband

<p>Truist Securities<strong> </strong>analyst <strong>Michael Ciarmoli</strong> revised the price forecast on <strong>RBC Bearings Incorporated</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBC#NYSE">RBC</a>) from $375 to $405, while keeping a Buy rating following the fourth quarter FY25 <a href="https://www.benzinga.com/quote/rbc/analyst-ratings" target="_blank" rel="noreferrer noopener">results reported on Friday</a>.</p>
<p>The analyst reported adjusted EPS of $2.83 beating the consensus of $2.70, while sales of $437.7 million <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45465327/rbc-bearings-incorporated-announces-fiscal-fourth-quarter-and-full-year-2025-results" rel="noreferrer noopener">missed the consensus of $440.3 million</a>.</p>
<p>The company expects first quarter sales of $424 million-$434 million&nbsp;<a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener">versus&nbsp;street view of $437.11 million</a>.</p>
<p>The analyst modestly increased the FY26 industrial revenue projections, considering the company&#8217;s proven ability to outperform the market, but remain somewhat cautious given the current macroeconomic environment.</p>
<p>Ciarmoli assumes that gross margin expansion of approximately 50-110 basis points in FY26 will be largely driven by the Aerospace &amp; Defense (A&amp;D) segment.</p>
<p>The analyst revised FY26 EPS estimates from $10.96 to $11.26 (versus consensus of $11.18) and sees FY26 EPS of $11.98.</p>
<p>Ciarmoli notes that tariff pressures are expected to have a minimal impact, and management believes they possess the ability to mitigate any headwinds.</p>
<p><strong>RBC</strong> <strong>Price Action:</strong> RBC shares are up 2.09% at $375.85 at publication on Monday.</p>
<p><strong>Read Next:</strong></p>
<ul class="wp-block-list">
<li><strong><a href="https://www.benzinga.com/markets/equities/25/05/45463291/wall-street-poised-to-open-higher-after-sp-500s-4-day-run-sounds-like-powell-is-expecting-more-frequent-bouts-of-stagflation-cautions-expert" target="_blank" rel="noreferrer noopener">Wall Street Poised To Open Higher After S&amp;P 500&#8217;s 4-Day Run: &#8216;Sounds Like Powell Is Expecting More Frequent Bouts Of Stagflation,&#8217; Cautions Expert&nbsp;</a></strong></li>
</ul>
<p><em>Photo: T. Schneider via Shutterstock</em></p>



Equities

Large Cap

RBC Bearings Can Defy Macro Headwinds, Says Analyst, On Aerospace Strength, Tariff Resilience

<p><a href="https://www.bloomberg.com/news/articles/2025-05-19/apple-must-resolve-fortnite-return-or-answer-for-it-to-judge?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-05-19/apple-must-resolve-fortnite-return-or-answer-for-it-to-judge?embedded-checkout=true</a></p>


General

AAPL

'Apple Must Resolve 'Fortnite' Return or Answer for It to Judge'- Bloomberg

<p><strong>JP Morgan</strong> analyst Lisa C. Gill revised her 2025 outlook on <strong>GoodRx Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDRX#NASDAQ">GDRX</a>) following the company&#8217;s first-quarter earnings. Gill reaffirmed an Overweight rating on the stock and maintained her $7 price forecast.</p>
<p>The company reported <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45266347/goodrx-reports-first-quarter-2025-results" rel="noreferrer noopener">first-quarter</a> 2025 revenue of $203 million (above the $202.21 million estimate), up 3% year-over-year. Adjusted EBITDA rose to $69.8 million, with margins improving to 34.4% from 31.7%. Net income came in at $11.1 million, reversing a $1 million loss in the prior year.</p>
<p>Pharma Manufacturer Solutions&#8217; revenue climbed 17%, while subscription revenue declined 7%, primarily due to the phaseout of the Kroger Savings Club.</p>
<p><strong><em>Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/25/05/45340465/bill-ackman-slams-subsidies-for-contributing-to-37-trillion-national-debt-hails-trumps-drug-price-order" rel="noreferrer noopener">Bill Ackman Slams Subsidies For Contributing To $37 Trillion National Debt, Hails Trump&#8217;s Drug Price Order</a></em></strong></p>
<p>GoodRx reaffirmed its full-year 2025 revenue outlook of $810-$840 million and raised its adjusted EBITDA forecast to $273–$287 million, compared to $260.2 million in 2024.</p>
<p>The analyst revised her 2025 revenue estimate slightly downward to $817 million (3% year-over-year growth), citing added ~$5 million in Rite Aid (RAD) headwinds, offset by strength in Pharma Manufacturer Solutions and improved margins.</p>
<p>She increased her adjusted EBITDA projection to $279 million (7% growth), with a 135 basis-point margin expansion to 34.2%. Despite a slight increase in sales and marketing expenses in the second half of 2025, margin strength is expected to persist.</p>
<p>Gill noted the trend of pharmacy costs shifting to consumers and the efforts of pharmacies/PBMs to capture abandoned scripts create a favorable environment for GoodRx&#8217;s value proposition.</p>
<p>The analyst anticipates solid growth, execution, and margin expansion with benefits from ISP adoption and increased consumerism in healthcare in 2025 and beyond.</p>
<p>JP Morgan maintained its December 2025 price target of $7, based on a 9x EV/EBITDA multiple on the 2026 forecast of $298 million and a sustained mid-to-high-single-digit EBITDA growth trajectory.</p>
<p><strong>Price Action:</strong> GDRX shares are trading lower by 0.88% to $3.93 at last check Monday.</p>
<p><strong><em>Read Next:</em></strong></p>
<ul class="wp-block-list">
<li><strong><em><a href="https://www.benzinga.com/25/05/45493652/700m-asset-manager-exits-unitedhealth-stock-says-medicare-advantage-is-facing-a-perfect-storm?utm_source=taboola&amp;utm_medium=exchange&amp;tblci=GiASBveH5OOleR_r1JTmHSM6Z-_lSH_9tK-aPxVzGmk7IiCN1Vco-rXxwNOCzNohMO-ISg#tblciGiASBveH5OOleR_r1JTmHSM6Z-_lSH_9tK-aPxVzGmk7IiCN1Vco-rXxwNOCzNohMO-ISg" target="_blank" rel="noreferrer noopener">EXCLUSIVE: UnitedHealth Gets Dumped, Why This Asset Manager Says Insurer Is No Longer A Safe Bet</a></em></strong></li>
</ul>
<p><em>Image by Aria Armoko via Shutterstock</em></p>


Analyst Color

Health Care

GDRX

GoodRx Offers Value Proposition As Pharmacy Costs Shifts To Consumers: Analyst

<p>Roth Capital  analyst Boobalan Pachaiyappan   maintains Cingulate (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CING#NASDAQ">CING</a>) with a Buy and lowers the price target from $12 to $11.</p>


CING

Roth Capital Maintains Buy on Cingulate, Lowers Price Target to $11

<p><a href="https://www.youtube.com/watch?v=KeGLM7JPPYo">https://www.youtube.com/watch?v=KeGLM7JPPYo</a></p>


Macro Economic Events

Economics

Federal Reserve

Fed's Kashkari Says Investor Confidence Is Key To Whether Debt Levels Are A Problem Or Not; Says There's More Of A Question About U.S. Long Term Role Right Now

<p>Oppenheimer  analyst Andreas Argyrides   downgrades Liquidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>) from Perform to Underperform and announces $13 price target.</p>


Downgrades

LQDA

Oppenheimer Downgrades Liquidia to Underperform, Announces $13 Price Target

<p>HG Vora Fights in Court to Have Votes for its Third Director Nominee, William Clifford, CountedUrges Shareholders to Vote for HG Vora's Three Independent Nominees on the GOLD Proxy Card to Send a Clear Message to PENN's
</p><p><i>HG Vora Fights in Court to Have Votes for its Third Director Nominee, William Clifford, Counted</i></p>
<p><i>Urges Shareholders to Vote for HG Vora's Three Independent Nominees on the GOLD Proxy Card to Send a Clear Message to PENN's Board that Shareholder-Led Change Is Needed</i></p>
<p>HG Vora Capital Management, LLC (together with its affiliates, "HG Vora") today issued the following statement regarding the acknowledgement buried in PENN Entertainment, Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENN#NASDAQ">PENN</a>) ("PENN" or the "Company") May 19, 2025 letter that it "will continue to consider opportunities to further refresh the Board" after the 2025 Annual Meeting of Shareholders (the "Annual Meeting") to be held on June 17, 2025. On April 25, 2025, PENN's Board unilaterally reduced the number of seats up for election at the Annual Meeting, which HG Vora believes was done to deprive shareholders of their fundamental right to elect three directors of their choosing.</p>
<p>"PENN's statement today reflects its continued and ongoing assault on shareholder rights and demonstrates the lengths this Board will go to entrench itself. PENN's statement suggests that it is going to expand the Board by adding back the seat that it removed last month and <strong>unilaterally</strong> name a director of its choosing for a three-year term – all <strong>after</strong> the 2025 Annual Meeting. These self-serving actions have no legitimate corporate purpose and are being done to deprive shareholders of the right to vote or oppose the nomination of a third director. <strong>This is simply unacceptable and should not be tolerated</strong>.</p>
<p>"HG Vora has nominated a highly qualified third independent director candidate in William Clifford and is now fighting in court for injunctive relief to have all votes for him counted at the Annual Meeting. Accordingly, HG Vora filed a motion on May 14, 2025 for expedited relief and a rapid trial in federal court in Pennsylvania, which PENN is opposing. HG Vora did not seek a preliminary injunction so the Board would not have the excuse to delay the Annual Meeting and avoid seating the other two HG Vora-nominated director candidates – Johnny Hartnett and Carlos Ruisanchez.</p>
<p>"Importantly, because of PENN's history of using the corporate machinery to thwart the will of shareholders, and its track record of value destruction, HG Vora believes shareholders should not tolerate such a manipulation of the electoral process and that PENN's Board has forfeited the right to select directors without shareholder input."</p>
<p>HG Vora encourages all shareholders to review its materials, which are available at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.WinAtPENN.com&amp;esheet=54257095&amp;newsitemid=20250519565617&amp;lan=en-US&amp;anchor=www.WinAtPENN.com&amp;index=1&amp;md5=b0270f2261de39d9dea98f284d8a9d88">www.WinAtPENN.com</a>.</p>


PENN

HG Vora Challenges PENN Entertainment's Board Maneuvers in Court, Calls For Shareholder Rights Protection

<p>During the last three months, 9 analysts shared their evaluations of Nabors Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NBR#NYSE">NBR</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Nabors Industries and provided 12-month price targets. The average target is $43.89, accompanied by a high estimate of $75.00 and a low estimate of $28.00. A 29.46% drop is evident in the current average compared to the previous average price target of $62.22. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747677717_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Nabors Industries by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eddie Kim</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$28.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Daniel Kutz</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$50.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Scott Gruber</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$38.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Keith Mackey</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$45.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Charles Minervino</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$29.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Charles Minervino</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$32.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Daniel Kutz</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Charles Minervino</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$45.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$53.00</td>
<td>$90.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Nabors Industries. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Nabors Industries compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Nabors Industries's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Nabors Industries's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/NBR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Nabors Industries analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Unveiling the Story Behind Nabors Industries</h2>
<p>Nabors Industries Ltd owns and operates land-based drilling rig fleets and is a provider of offshore platform rigs in the United States and international markets. It also provides performance tools, directional drilling services, tubular running services, and technologies. The company has four reportable segments: U.S. Drilling, International Drilling, Drilling Solutions, and Rig Technologies. The key revenue of the company is generated from International Drilling.</p>
<h3>Financial Milestones: Nabors Industries's Journey</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Nabors Industries's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately <strong>0.87%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Energy sector.</p>
<p><strong>Net Margin:</strong> Nabors Industries's net margin excels beyond industry benchmarks, reaching <strong>4.48%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Nabors Industries's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>13.81%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Nabors Industries's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>0.69%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Nabors Industries's debt-to-equity ratio surpasses industry norms, standing at <strong>7.84</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


What Analysts Are Saying About Nabors Industries Stock

<p>Analysts' ratings for FedEx (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) over the last quarter vary from bullish to bearish, as provided by 21 analysts.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">10</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $286.9, a high estimate of $354.00, and a low estimate of $220.00. This current average has decreased by 8.89% from the previous average price target of $314.90. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747677705_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>A clear picture of FedEx's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fadi Chamoun</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$260.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Ken Hoexter</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$270.00</td>
<td>$272.00</td>
</tr>
<tr>
<td>Lucas Servera</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$275.00</td>
<td>$305.00</td>
</tr>
<tr>
<td>Christian Wetherbee</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$220.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Ariel Rosa</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$267.00</td>
<td>$305.00</td>
</tr>
<tr>
<td>Stephanie Moore</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$275.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Ariel Rosa</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$305.00</td>
<td>$317.00</td>
</tr>
<tr>
<td>Brandon Oglenski</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$350.00</td>
<td>$365.00</td>
</tr>
<tr>
<td>Brian Ossenbeck</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$280.00</td>
<td>$323.00</td>
</tr>
<tr>
<td>Thomas Wadewitz</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$331.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Fadi Chamoun</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$275.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>Christian Wetherbee</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$260.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Daniel Imbro</td>
<td>Stephens &amp; Co.</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$300.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Rick Paterson</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Sell</td>
<td>$221.00</td>
<td>$283.00</td>
</tr>
<tr>
<td>Patrick Tyler Brown</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$290.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>J. Bruce Chan</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$354.00</td>
<td>$364.00</td>
</tr>
<tr>
<td>Ken Hoexter</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$272.00</td>
<td>$295.00</td>
</tr>
<tr>
<td>Ariel Rosa</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$317.00</td>
<td>$347.00</td>
</tr>
<tr>
<td>Lucas Servera</td>
<td>Truist Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$305.00</td>
<td>-</td>
</tr>
<tr>
<td>Christian Wetherbee</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$275.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Brian Ossenbeck</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$323.00</td>
<td>$372.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to FedEx. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of FedEx compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Capture valuable insights into FedEx's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/FDX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on FedEx analyst ratings.</strong></a></p>
<h2>Discovering FedEx: A Closer Look</h2>
<p>FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2024, which ended in May, FedEx derived 47% of revenue from its express division, 37% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder came from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016, boosting its presence across Europe. TNT was previously the fourth-largest global parcel delivery provider.</p>
<h3>FedEx: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Revenue Growth:</strong> FedEx's revenue growth over a period of 3M has been noteworthy. As of 28 February, 2025, the company achieved a revenue growth rate of approximately <strong>1.94%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> FedEx's net margin excels beyond industry benchmarks, reaching <strong>4.1%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> FedEx's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>3.42%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> FedEx's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>1.06%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> FedEx's debt-to-equity ratio is below the industry average at <strong>1.39</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


The Analyst Verdict: FedEx In The Eyes Of 21 Experts

<p>Deep-pocketed investors have adopted a bullish approach towards Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in SMCI usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 39 extraordinary options activities for Super Micro Computer. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 51% leaning bullish and 41% bearish. Among these notable options, 7 are puts, totaling $258,900, and 32 are calls, amounting to $1,989,142.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $25.0 to $55.0 for Super Micro Computer during the past quarter. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of Super Micro Computer stands at 4583.46, with a total volume reaching 46,338.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Super Micro Computer, situated within the strike price corridor from $25.0 to $55.0, throughout the last 30 days.</p>
<h3>Super Micro Computer Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747677696_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>SMCI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$10.55</td>
<td>$10.4</td>
<td>$10.45</td>
<td>$50.00</td>
<td>$365.7K</td>
<td>19.1K</td>
<td align="right">782</td>
</tr>
<tr>
<td>SMCI</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/15/25</td>
<td>$5.45</td>
<td>$5.35</td>
<td>$5.4</td>
<td>$51.00</td>
<td>$270.0K</td>
<td>3.4K</td>
<td align="right">511</td>
</tr>
<tr>
<td>SMCI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$16.6</td>
<td>$16.55</td>
<td>$16.6</td>
<td>$36.00</td>
<td>$166.0K</td>
<td>2.1K</td>
<td align="right">101</td>
</tr>
<tr>
<td>SMCI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$18.05</td>
<td>$17.8</td>
<td>$18.05</td>
<td>$34.00</td>
<td>$108.3K</td>
<td>1.1K</td>
<td align="right">60</td>
</tr>
<tr>
<td>SMCI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$4.25</td>
<td>$4.15</td>
<td>$4.15</td>
<td>$50.00</td>
<td>$83.0K</td>
<td>2.0K</td>
<td align="right">657</td>
</tr>
</tbody>
</table>
</p>
<h3>About Super Micro Computer</h3>
<p>Super Micro Computer Inc provides high-performance server technology services to cloud computing, data centers, Big Data, high-performance computing, and the "Internet of Things" embedded markets. Its solutions include server, storage, blade, and workstations to full racks, networking devices, and server management software. The firm follows a modular architectural approach, which provides flexibility to deliver customized solutions. The Company operates in one operating segment that develops and provides high-performance server solutions based upon an innovative, modular, and open-standard architecture. More than half of the firm's revenue is generated in the United States, with the rest coming from Europe, Asia, and other regions.</p>
<h3>Current Position of Super Micro Computer</h3>
<ul>
<li>With a trading volume of 34,481,998, the price of SMCI is down by -2.12%, reaching $45.17.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 78 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Super Micro Computer</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $35.2.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Equal-Weight rating on Super Micro Computer with a target price of $34.<br />
&#x2A; An analyst from Raymond James has revised its rating downward to Outperform, adjusting the price target to $41.<br />
&#x2A; An analyst from Wedbush persists with their Neutral rating on Super Micro Computer, maintaining a target price of $30.<br />
&#x2A; Consistent in their evaluation, an analyst from Mizuho keeps a Neutral rating on Super Micro Computer with a target price of $34.<br />
&#x2A; An analyst from Citigroup persists with their Neutral rating on Super Micro Computer, maintaining a target price of $37. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Super Micro Computer with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


Options

Markets

SMCI

Super Micro Computer Unusual Options Activity For May 19

<p>In the preceding three months, 5 analysts have released ratings for Rithm Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RITM#NYSE">RITM</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $13.5, a high estimate of $14.00, and a low estimate of $12.50. This current average reflects an increase of 0.75% from the previous average price target of $13.40. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747677691_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The standing of Rithm Capital among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jay McCanless</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Jason Weaver</td>
<td>Jones Trading</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.50</td>
<td>$12.50</td>
</tr>
<tr>
<td>Crispin Love</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$14.00</td>
<td>$12.50</td>
</tr>
<tr>
<td>Douglas Harter</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$13.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Jay McCanless</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Rithm Capital. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Rithm Capital compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Rithm Capital's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Rithm Capital's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/RITM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Rithm Capital analyst ratings.</strong></a></p>
<h2>About Rithm Capital</h2>
<p>Rithm Capital Corp operates as a real estate investment trust that provides capital and services to the real estate and financial services industries. The company aims to generate attractive risk-adjusted returns in all interest-rate environments through a complementary portfolio of investments and operating businesses. Its investment portfolio is composed of mortgage servicing-related assets (full and excess MSRs and servicer advances), residential securities (and associated call rights) loans (including single-family rental), and consumer loans. Its operating segments are Origination and Servicing; Investment Portfolio; Residential Transitional Lending; and Asset Management.</p>
<h3>Financial Milestones: Rithm Capital's Journey</h3>
<p><strong>Market Capitalization:</strong> Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Rithm Capital's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately <strong>-36.9%</strong> in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>7.41%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Rithm Capital's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>0.56%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Rithm Capital's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>0.08%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Rithm Capital's debt-to-equity ratio surpasses industry norms, standing at <strong>4.94</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


RITM

A Glimpse Into The Expert Outlook On Rithm Capital Through 5 Analysts

<p>Financial giants have made a conspicuous bullish move on JD.com. Our analysis of options history for JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) revealed 11 unusual trades.</p>
<p>Delving into the details, we found 45% of traders were bullish, while 45% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $574,390, and 7 were calls, valued at $362,892.</p>
<h3>Projected Price Targets</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $27.5 to $45.0 for JD.com over the last 3 months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of JD.com stands at 2552.36, with a total volume reaching 6,056.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in JD.com, situated within the strike price corridor from $27.5 to $45.0, throughout the last 30 days.</p>
<h3>JD.com Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747677690_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>JD</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$1.19</td>
<td>$1.07</td>
<td>$1.13</td>
<td>$28.00</td>
<td>$423.7K</td>
<td>2.7K</td>
<td>3.7K</td>
</tr>
<tr>
<td>JD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$4.75</td>
<td>$4.7</td>
<td>$4.72</td>
<td>$35.00</td>
<td>$141.6K</td>
<td>2.3K</td>
<td>380</td>
</tr>
<tr>
<td>JD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$9.05</td>
<td>$7.9</td>
<td>$7.9</td>
<td>$37.00</td>
<td>$69.5K</td>
<td>1.5K</td>
<td>88</td>
</tr>
<tr>
<td>JD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$3.75</td>
<td>$3.7</td>
<td>$3.7</td>
<td>$37.50</td>
<td>$55.1K</td>
<td>4.9K</td>
<td>162</td>
</tr>
<tr>
<td>JD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$1.86</td>
<td>$1.82</td>
<td>$1.86</td>
<td>$33.00</td>
<td>$46.5K</td>
<td>701</td>
<td>284</td>
</tr>
</tbody>
</table>
</p>
<h3>About JD.com</h3>
<p>JD.com is the third-largest Chinese e-commerce platform by GMV in 2024. it offers a wide selection of authentic products with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.</p>
<p>Having examined the options trading patterns of JD.com, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Where Is JD.com Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 4,784,311, the JD's price is down by -0.13%, now at $33.51. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 87 days.</li>
</ul>
<h3>Expert Opinions on JD.com</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $45.4.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Mizuho continues to hold a Outperform rating for JD.com, targeting a price of $48.<br />
&#x2A; An analyst from Benchmark has decided to maintain their Buy rating on JD.com, which currently sits at a price target of $53.<br />
&#x2A; An analyst from Macquarie downgraded its action to Neutral with a price target of $35.<br />
&#x2A; Consistent in their evaluation, an analyst from Susquehanna keeps a Neutral rating on JD.com with a target price of $40.<br />
&#x2A; An analyst from Citigroup has decided to maintain their Buy rating on JD.com, which currently sits at a price target of $51. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for JD.com, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Unpacking the Latest Options Trading Trends in JD.com

<p>Deep-pocketed investors have adopted a bullish approach towards Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in JNJ usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options activities for Johnson &amp; Johnson. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 54% leaning bullish and 45% bearish. Among these notable options, 6 are puts, totaling $391,310, and 5 are calls, amounting to $251,653.</p>
<h3>Predicted Price Range</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $150.0 to $165.0 for Johnson &amp; Johnson over the recent three months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of Johnson &amp; Johnson stands at 795.6, with a total volume reaching 5,482.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Johnson &amp; Johnson, situated within the strike price corridor from $150.0 to $165.0, throughout the last 30 days.</p>
<h3>Johnson &amp; Johnson 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747677685_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$14.55</td>
<td>$14.35</td>
<td>$14.35</td>
<td>$165.00</td>
<td>$119.1K</td>
<td>2.5K</td>
<td>83</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/27/25</td>
<td>$5.05</td>
<td>$4.65</td>
<td>$4.65</td>
<td>$150.00</td>
<td>$93.0K</td>
<td>136</td>
<td>206</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$10.7</td>
<td>$10.0</td>
<td>$10.6</td>
<td>$160.00</td>
<td>$91.1K</td>
<td>123</td>
<td>86</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/23/25</td>
<td>$0.82</td>
<td>$0.81</td>
<td>$0.81</td>
<td>$150.00</td>
<td>$81.1K</td>
<td>1.4K</td>
<td>3.2K</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/30/25</td>
<td>$0.78</td>
<td>$0.75</td>
<td>$0.78</td>
<td>$155.00</td>
<td>$53.5K</td>
<td>643</td>
<td>1.2K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Johnson &amp; Johnson</h3>
<p>Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.</p>
<p>In light of the recent options history for Johnson &amp; Johnson, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Where Is Johnson &amp; Johnson Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 3,885,401, the JNJ's price is up by 0.28%, now at $151.75. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 58 days.</li>
</ul>
<h3>Expert Opinions on Johnson &amp; Johnson</h3>
<p>1 market experts have recently issued ratings for this stock, with a consensus target price of $153.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Leerink Partners has revised its rating downward to Market Perform, adjusting the price target to $153. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Johnson &amp; Johnson, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Market Whales and Their Recent Bets on JNJ Options

<p>Analysts' ratings for Norwegian Cruise Line (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) over the last quarter vary from bullish to bearish, as provided by 19 analysts.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">9</td>
<td align="right">4</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Norwegian Cruise Line, revealing an average target of $25.95, a high estimate of $36.00, and a low estimate of $18.00. Experiencing a 11.94% decline, the current average is now lower than the previous average price target of $29.47. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747677683_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Norwegian Cruise Line. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Scholes</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$27.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Paul Golding</td>
<td>Macquarie</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$27.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Stephen Grambling</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Laura Champine</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$24.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Steven Wieczynski</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$26.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Christopher Stathoulopoulos</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Lizzie Dove</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$20.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Brandt Montour</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Laura Champine</td>
<td>Loop Capital</td>
<td>Announces</td>
<td>Buy</td>
<td>$25.00</td>
<td>-</td>
</tr>
<tr>
<td>Steven Wieczynski</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$30.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Stephen Grambling</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$21.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>David Katz</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$25.00</td>
<td>-</td>
</tr>
<tr>
<td>Stephen Grambling</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$22.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Ivan Feinseth</td>
<td>Tigress Financial</td>
<td>Maintains</td>
<td>Strong Buy</td>
<td>$36.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Andrew Didora</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$26.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Paul Golding</td>
<td>Macquarie</td>
<td>Raises</td>
<td>Outperform</td>
<td>$31.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>James Hardiman</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$34.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Daniel Politzer</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$28.00</td>
<td>$27.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Norwegian Cruise Line. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Norwegian Cruise Line compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Norwegian Cruise Line's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/NCLH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Norwegian Cruise Line analyst ratings.</strong></a></p>
<h2>About Norwegian Cruise Line</h2>
<p>Norwegian Cruise Line is the world's third-largest publicly traded cruise company by berths (around 70,000). It operates 33 ships across three brands—Norwegian, Oceania, and Regent Seven Seas—offering both freestyle and luxury cruising. The company redeployed its entire fleet as of May 2022. With 12 passenger vessels on order among its brands through 2036, representing 37,500 incremental berths, Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sails to around 700 global destinations.</p>
<h3>Breaking Down Norwegian Cruise Line's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Challenges:</strong> Norwegian Cruise Line's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately <strong>-2.91%</strong>. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Norwegian Cruise Line's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-1.89%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Norwegian Cruise Line's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-2.84%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Norwegian Cruise Line's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-0.19%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Norwegian Cruise Line's debt-to-equity ratio surpasses industry norms, standing at <strong>9.88</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


NCLH

Forecasting The Future: 19 Analyst Projections For Norwegian Cruise Line

<p><strong>Paycom Software's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAYC#NYSE">PAYC</a>) short percent of float has risen 6.18% since its last report. The company recently reported that it has <strong>1.77 million shares sold short</strong>, which is 3.78% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 4.08 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>Paycom Software Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747677682_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Paycom Software has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Paycom Software's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Paycom Software's peer group average for short interest as a percentage of float is 5.55%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

PAYC

Is the Market Bullish or Bearish on Paycom Software?

<p><strong>Northrop Grumman's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>) short percent of float has risen 18.12% since its last report. The company recently reported that it has <strong>2.71 million shares sold short</strong>, which is 1.89% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 1.52 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>Northrop Grumman Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747677676_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Northrop Grumman has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Northrop Grumman's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Northrop Grumman's peer group average for short interest as a percentage of float is 4.83%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Is Northrop Grumman Gaining or Losing Market Support?

<p>Analysts' ratings for Solventum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOLV#NYSE">SOLV</a>) over the last quarter vary from bullish to bearish, as provided by 9 analysts.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Solventum, presenting an average target of $80.22, a high estimate of $87.00, and a low estimate of $71.00. Observing a 6.8% increase, the current average has risen from the previous average price target of $75.11. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747677672_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>A comprehensive examination of how financial experts perceive Solventum is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$87.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$78.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$80.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$80.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Steven Valiquette</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$82.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Sell</td>
<td>$71.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Vik Chopra</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$75.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$84.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Travis Steed</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$80.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Solventum. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Solventum compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Solventum's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Solventum's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SOLV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Solventum analyst ratings.</strong></a></p>
<h2>Get to Know Solventum Better</h2>
<p>Solventum Corp is a healthcare company developing, manufacturing, and commercializing a portfolio of solutions that leverage deep material science, data science, and digital capabilities to address critical customer and patient needs. The company has four operating segments: MedSurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The company generates the majority of its revenue from the MedSurg segment, which provides wound care and surgical solutions that are intended to accelerate healing, prevent complications, and lower the total cost of care globally.</p>
<h3>Solventum: Financial Performance Dissected</h3>
<p><strong>Market Capitalization:</strong> Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.</p>
<p><strong>Revenue Growth:</strong> Solventum displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately <strong>2.68%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Solventum's net margin excels beyond industry benchmarks, reaching <strong>6.62%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Solventum's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>4.4%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Solventum's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>0.95%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>2.43</strong>, Solventum faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


SOLV

Assessing Solventum: Insights From 9 Financial Analysts

Press Releases

Nuvation Bio to Present at the TD Cowen 45th Annual Health Care Conference

Nuvation Bio Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners

Nuvation Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Crizotinib During Mini Oral Presentation at the European Lung Cancer Congress 2025

Comments

Nuvation Bio

ニュース

最新ニュース Nuvation Bio (NYSE:NUVB) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル